"All my biologics have failed" usually means the drugs a person has tried so far did not control their Crohn's disease, not that medicine has nothing left to offer. Crohn's disease is a lifelong inflammatory bowel disease (IBD) that can inflame any part of the gut, and biologics are protein medicines that block specific immune signals. When several fail, teams typically recheck drug levels, confirm what is causing symptoms, then weigh untried drug classes, surgery, combination therapy, trials and nutrition support (AGA guideline 2025).
This article lays out those options and the evidence behind each, including where the evidence is thin. It describes research. It is not advice to start, stop, switch or taper any medicine, and none of it replaces your IBD team, who know your scans, history and risks.
What does "failing all biologics" actually mean?
It means the biologics tried so far did not bring or keep the disease under control, either from the start (primary non-response) or after an initial benefit faded (secondary loss of response). It does not mean every biologic ever made has been tried, and it does not describe your future. Doctors usually count failure by drug class, not by the number of brand names.
That distinction matters because the phrase hides three different situations:
- Primary non-response: no meaningful improvement after the induction period.
- Secondary loss of response: a good response that wore off. In the UK PANTS cohort, among people who first responded, an estimated 60.0% on infliximab and 68.4% on adalimumab had lost response by year 3 (Chanchlani 2024).
- Intolerance: the drug works but side effects or reactions stop it.
Each leads to a different next step. If you want the longer breakdown of causes, our guide to what it means when a biologic stops working walks through them, and how often people switch biologics shows how common changing drugs is in real-world data.
Why do biologics fail in Crohn's disease?
Biologics fail for several reasons that are not mutually exclusive: too little drug reaching the target, the immune system making antibodies against the drug, the disease being driven by a pathway the drug does not block, or symptoms coming from something other than active inflammation, such as scarring. Each reason points to a different fix. If the antibody route is the one in question, what to do if you develop infliximab antibodies covers how low-level and high-titer results are handled differently.
Not enough drug. Drug concentration in the blood varies between people. In PANTS, low anti-TNF concentrations at week 14 predicted loss of response by years 2 and 3 for both infliximab and adalimumab (Chanchlani 2024).
Anti-drug antibodies. By the end of year 3, an estimated 44.0% of people on infliximab and 20.3% on adalimumab had developed antibodies associated with undetectable drug levels. Taking an immunomodulator alongside the biologic was associated with fewer antibodies in both groups (Chanchlani 2024). These are associations in an observational cohort, but they explain why combination therapy with a thiopurine is something the AGA guideline suggests for infliximab (AGA guideline 2025).
A different disease driver. Crohn's inflammation runs through several immune pathways. A drug that blocks TNF may do little when another pathway dominates, which is part of why switching class can help even after an earlier failure.
Not inflammation at all. Narrowed bowel (a stricture), bacterial overgrowth, infection, bile acid problems and irritable bowel overlap can all mimic a flare. This is why teams re-confirm active disease before declaring failure.
| Reason a biologic seems to fail | What the team may check | Where it can lead |
|---|---|---|
| Low drug level | Blood drug concentration | Adjusting the same drug, or changing drug |
| Anti-drug antibodies | Antibody test alongside the level | Adding an immunomodulator, or changing drug |
| Wrong target for your disease | Scope, imaging, biomarkers | Changing drug class |
| Stricture or scarring, not inflammation | MRI, ultrasound, endoscopy | Endoscopic or surgical options |
| Infection or other cause | Stool tests, bloods | Treating the other cause |
What should be checked before a biologic is called a failure?
Experts recommend confirming that inflammation is truly present and measuring drug levels and antibodies before labeling a biologic a failure. A 2021 expert consensus said reactive therapeutic drug monitoring (checking levels when a drug seems not to work) should be used for all biologics, for both primary non-response and secondary loss of response (Cheifetz 2021).
In practice a thorough workup after a drug appears to stop working often includes some of the following. Your team decides which apply: Related: can you stop Crohn's medication in remission?
- Objective evidence of inflammation. Symptoms are poor guides to inflammation in Crohn's. Blood and stool markers, colonoscopy, MRI or bowel ultrasound show whether the bowel is actually inflamed. Our explainer on intestinal ultrasound versus colonoscopy covers the tests.
- Drug level and antibody test. A trough level and, where relevant, an antibody result. The consensus panel also supported proactive monitoring for anti-TNF drugs after induction and during maintenance (Cheifetz 2021).
- A look for complications. Strictures, abscesses and fistulas can need drainage or surgery regardless of which drug is used.
- A look for infection and other causes. Including infection and medicines that irritate the gut.
- A medication history. Which classes were tried, for how long, at what level, and why each stopped.
If your records show a drug was stopped early or never reached an adequate level, that is a useful thing to raise with your specialist. It is not a reason to restart or stop anything on your own. For help structuring that conversation, see our list of questions to ask your doctor about Crohn's disease.
What treatment options exist after several biologics?
The main options are a drug from a class not yet tried, a different drug in the same class after optimizing it, combination therapy with an immunomodulator or a second advanced therapy, surgery, clinical trials, and nutrition support alongside medication. Which are realistic depends on your disease location, complications, past drug history and what your country's insurers or health system cover. For the earlier question of how the classes compare when you are choosing a first or second drug, see which biologic is best for Crohn's disease.
| Option | Strength of evidence | Main caution |
|---|---|---|
| IL-23 inhibitors (risankizumab, guselkumab) | Phase 3 randomized trials, including biologic-exposed adults | Fewer long-term data than older drugs |
| JAK inhibitor (upadacitinib) | Phase 3 randomized trials | Infection (herpes zoster) and other safety monitoring |
| Ustekinumab or mirikizumab | Ustekinumab: phase 3 trial in people with anti-TNF non-response. Mirikizumab: guideline-listed | Both rated intermediate efficacy in the AGA guideline |
| Immunomodulator added to a biologic | Guideline suggests for infliximab | Not suited to everyone, needs monitoring |
| Two advanced therapies together | Small, mostly observational studies | Very low certainty, limited access |
| Surgery | Randomized trial in earlier disease, mostly observational otherwise | Operation risks, recurrence can occur |
| Clinical trials | Varies by trial | Placebo or unknown benefit |
| Stem cell transplant | One randomized trial, no significant benefit | Serious toxicity, experimental |
| Diet and nutrition therapy | An adult trial in mild-to-moderate disease, not in refractory disease | Adjunct, not a replacement |
The 2025 AGA guideline makes this concrete. For adults who have previously been exposed to one or more advanced therapies, it suggests choosing a higher efficacy medication (adalimumab, risankizumab, guselkumab or upadacitinib) or an intermediate one (ustekinumab or mirikizumab) over a lower efficacy one (vedolizumab or certolizumab pegol) (AGA guideline 2025). The ACG's 2025 guideline similarly stresses shared decision-making between patient and clinician (ACG guideline 2025). These are population-level suggestions, not instructions for any one person.
Drug approval status, labels and funding differ between the US, UK, Canada and Australia and change often, so ask your specialist what is available to you.
Do newer drugs like IL-23 inhibitors and upadacitinib work after other biologics?
Yes, in randomized trials. IL-23 inhibitors and the JAK inhibitor upadacitinib beat placebo in people with moderate-to-severe Crohn's disease, including groups who had already tried biologics. A 2025 network meta-analysis found moderate-to-high certainty evidence for risankizumab, guselkumab and upadacitinib in biologic-exposed adults (Singh 2025).
What the trials showed:
- Risankizumab (IL-23 inhibitor). In MOTIVATE, which enrolled people with prior biologic failure, week-12 clinical remission by the activity-index definition was 40% to 42% with risankizumab versus 20% with placebo, and endoscopic response was 29% to 34% versus 11% (D'Haens 2022).
- Guselkumab (IL-23 inhibitor). In the GALAXI-2 and GALAXI-3 trials, the combined endpoint of week-12 response plus week-48 clinical remission was reached by 47% to 55% across guselkumab regimens versus 12% to 13% with placebo (Panaccione 2025).
- Upadacitinib (JAK inhibitor). In the two induction trials, clinical remission at week 12 was 49.5% versus 29.1% (U-EXCEL) and 38.9% versus 21.1% (U-EXCEED), and at week 52 in people who had responded, 37.3% to 47.6% depending on the maintenance regimen versus 15.1% with placebo (Loftus 2023).
- Ustekinumab (IL-12/23 inhibitor). In UNITI-1, which enrolled people who had not responded to or could not tolerate TNF antagonists, week-6 response was about 34% versus 21.5% with placebo (Feagan 2016).
Three honest limits apply. First, these are averages across hundreds of people: a rate of 40% means most trial participants did not reach that endpoint at that time. Second, most trials are funded by the manufacturer and differ in design, so you cannot compare percentages across them. Third, safety matters. In the upadacitinib program, herpes zoster occurred more often than with placebo at higher doses, hepatic disorders and neutropenia were more frequent in one maintenance group, and gastrointestinal perforation occurred in a small number of participants (Loftus 2023). A JAK inhibitor is not a simple swap, which is why it is a prescriber-level conversation about your risk factors.
People in r/CrohnsDisease often describe this stage as a roller coaster: some report long remissions on a JAK inhibitor after several biologics, others say it did not work and describe feeling dropped by their team (r/CrohnsDisease thread). Both stories fit the trial data, because a response rate under 50% means non-responders are common even with newer drugs.
Can you take two biologics, or a biologic plus a small-molecule drug?
Sometimes, in specialist centers, but the evidence is weak. Combining two advanced therapies (dual therapy) has only been studied in small, mostly observational reports. A meta-analysis of 30 studies found pooled clinical remission of 59%, yet the authors said it may be an option only in highly selected people at specialized centers (Ahmed 2022).
The details:
- That meta-analysis covered 288 treatment courses in 279 people, 76% with Crohn's disease, most of whom had medically refractory disease. Pooled rates were 59% clinical remission, 34% endoscopic remission, 31% any adverse event, 6.5% serious adverse event, and 12% needed surgery (Ahmed 2022).
- A second review of 13 studies (one trial, 12 observational) concluded combination therapy "appears to be generally safe and may be effective" but rated the certainty of evidence very low (Alayo 2022).
- Using an immunomodulator with a single biologic is a different, better-studied strategy. The AGA suggests combining infliximab with a thiopurine over infliximab alone, particularly in people who have not had a thiopurine before (AGA guideline 2025).
Reddit conversations on this topic usually pair two ideas: dual therapy is attractive, and insurance is the obstacle, since the combinations are generally used off label. We could not verify coverage rules in general, so ask your team and your insurer or health service directly. Because the data are limited, this is a decision for an IBD center with experience, not something to chase on your own.
When is surgery an option for Crohn's that biologics did not control?
Surgery removes the diseased section of bowel rather than suppressing the immune system, and for some people it is an alternative or complement to drugs. In the LIR!C trial of ileocaecal Crohn's, 10-year therapy-free remission was 35.8% after resection versus 13.2% with infliximab, though overall clinical remission was similar between groups (Oldenburg 2026).
Read that carefully. LIR!C enrolled adults with non-stricturing, immunomodulator-refractory disease limited to the ileocaecal area, comparing surgery with infliximab as a first biologic. It did not enroll people who had failed several biologics, so it shows what resection can do in a defined group, not what it will do for you (Oldenburg 2026). We did not find a randomized trial of surgery specifically in people who had failed multiple biologics, and the evidence there is mostly observational and based on specialist experience.
What surgery can and cannot do:
- It can remove segments with strictures, fistulas or abscesses that no drug will fix.
- Some patients in online discussions describe surgery as "a tool, not a dead end", for example hoping that removing the worst segment leaves less disease for drugs to control. We did not find trial evidence in biologic-refractory disease that confirms this, so treat it as an idea to discuss with a surgeon, not an expected result.
- Crohn's can recur after resection, so most people continue some form of follow-up and often medication.
- Operations carry risks, and bowel length matters if several resections are needed.
If surgery comes up, a colorectal surgeon who regularly treats Crohn's and a stoma (WOC) nurse can explain the options, including the possibility of a temporary or permanent stoma, in plain language. Our post on a food diary after Crohn's bowel resection shows what day-to-day life after bowel surgery can involve.
Can clinical trials or stem cell transplant help?
Clinical trials are a real route to treatments not yet approved, and large IBD centers run many. Autologous stem cell transplant, by contrast, is experimental: in the ASTIC randomized trial, sustained remission at 1 year was 8.7% with transplant versus 4.5% with usual care, a gap that was not statistically significant (Hawkey 2015).
Trials in general. Trials test new drugs, new combinations or new strategies. A person in r/CrohnsDisease may describe being told that a research hospital is the best route to newer options, and that is plausible because trials usually run at large centers. Questions worth asking before joining:
- Could I receive a placebo, and for how long?
- What happens to my current treatment during the study?
- What are the inclusion and exclusion criteria, and what are the known side effects so far?
- What are the visit and travel demands?
- What happens to me if the drug works, or if it does not?
You can search ClinicalTrials.gov with the terms "Crohn's disease" and your location, and the Crohn's and Colitis Foundation in the US and Crohn's and Colitis UK both publish information on research opportunities. Eligibility is strict, so being eligible for one trial is not a given.
Stem cell transplant. Hawkey and colleagues tested autologous hematopoietic stem cell transplant in 45 adults aged 18 to 50 with refractory Crohn's disease that was not amenable to surgery after treatment with three or more immunosuppressive or biologic agents and steroids. Sustained remission at 1 year was 2 of 23 (8.7%) with transplant and 1 of 22 (4.5%) in controls, with 76 serious adverse events in the transplant group versus 38 in controls, and one death in the transplant group. The authors concluded the findings did not support widespread use (Hawkey 2015). Some people on transplant did stop immunosuppressive or biologic drugs for at least 3 months, but the trial's main goal was not met. Stem cell approaches remain research, not a standard option.
Does nutrition therapy help alongside medication?
Diet and nutrition therapy can support treatment, but the adult trial evidence we reviewed is in mild-to-moderate disease and it is not a substitute for medication in people whose Crohn's is active after several biologics. One adult trial tested the Crohn's disease exclusion diet in mild-to-moderate disease, not in people who had failed multiple drugs (Yanai 2022).
That is why we describe nutrition here as supportive:
- If you have a stricture, a low-residue or modified-texture diet may be advised by your dietitian to reduce obstruction risk. This is individual advice from a specialist IBD dietitian.
- Malnutrition and vitamin deficiencies are common in active Crohn's, and a dietitian can check them. Our post on controlling Crohn's with diet alone covers what the evidence does and does not support, and what to eat during a flare is a practical companion.
- Exclusive or partial enteral nutrition and structured exclusion diets are specialist-supervised approaches. Do not start one on your own.
Be wary of anyone who says diet alone should replace medicine after biologics have failed. The evidence does not support that, and uncontrolled inflammation can cause lasting bowel damage.
What warning signs need urgent care?
Severe or worsening abdominal pain, repeated vomiting, a swollen firm belly, being unable to pass gas or stool, fever, a racing heart, heavy rectal bleeding, or signs of dehydration need urgent medical care the same day. These can signal a bowel blockage, a perforation, an abscess or serious inflammation, none of which should be managed with a wait-and-see approach.
Also see your IBD team promptly (not necessarily the emergency room) for new unexplained weight loss, ongoing fever or night sweats, new or worsening perianal pain or discharge, or a clear change in your usual pattern. Do not stop or skip treatment on your own because a drug "failed," and do not restart an old drug without talking to your prescriber. Our guide on how to tell if you are in a Crohn's flare can help you spot a pattern, but it is no substitute for urgent assessment when you are unwell.
What do people in r/CrohnsDisease say about running out of options?
A common theme is relief that failing a few drugs is not the end. Commenters in a thread titled around failing mainline biologics within two years mentioned combination therapy with an immunomodulator, untried biologics and newer classes, surgery, clinical trials and care at a research hospital (r/CrohnsDisease). Another widely read thread asks what happens if you fail all biologics (r/CrohnsDisease).
These threads are lived experience, not evidence. What they show well is the emotional side: fear after a doctor says "we are running out," frustration with insurance, and mixed experiences with newer drugs. They also show how much people's situations differ across countries, which is why a UK commenter listing seven biologics and a US commenter worried about insurance can both be correct about their own system.
What should I ask my IBD team?
Bring specific questions, since "what is next" gets a vague answer. Useful ones:
- Which drug classes have I used, and which have I not?
- Were my drug levels and antibodies checked for each failed drug? What were they?
- Do my scans or scope show active inflammation, a stricture, or something else?
- Is any option here an off-label use, and how would coverage work?
- Would an immunomodulator or a combination make sense for me?
- Should a surgeon review my case, and what would surgery involve?
- Are there clinical trials at this center or nearby that I could be eligible for?
- Would a referral to a specialist IBD center or a second opinion help?
- What would a good response look like, and when will we judge it?
- Should I see an IBD dietitian?
How can tracking help after a biologic fails?
A clear record makes the "did it work" judgment easier because Crohn's fluctuates and memory is unreliable. Logging stool frequency, urgency, pain, blood, nighttime symptoms, steroid courses, infusion or injection dates and side effects gives your team a timeline they can compare against blood tests, scans and drug levels.
If you want to try this, a free-to-download tracker such as Clairop can log symptoms and medication timing and turn them into a summary you can bring to appointments. It does not diagnose or recommend treatment, and it sits alongside your care. See how it works, or compare options in our list of apps for Crohn's disease. For a visit-ready format, our guide to a symptom tracker for doctor visits shows what clinicians find useful.
Clairop logs meals, symptoms and stool in seconds, then looks for the foods your gut reacts to, including reactions that land days later.
Common myths about failing biologics
"Three failed biologics means I have no options left." Guidelines list drugs across several classes plus surgery and trials, and the number of brand names tried is not the number of classes (AGA guideline 2025).
"If a drug failed once, it will never work." Sometimes a drug failed because levels were low or antibodies formed, and that can change the picture. That is a question for your team, not a signal to restart anything yourself (Cheifetz 2021).
"Surgery means I failed." Surgery is a recognized treatment and some patients describe it as a reset. It does carry risks and Crohn's can return.
"Newer drugs are always better." Trials show benefit versus placebo, but response rates are well under 100%, and no head-to-head data settle every comparison (Singh 2025).
"Diet can replace my medication." The best diet trials are in milder disease, and diet is supportive rather than a replacement.
"A stem cell transplant is the next step." It is experimental, with serious toxicity in the randomized trial (Hawkey 2015).
What to take from this
Failing biologics is hard, and the options that remain are real but uneven in evidence. Drug-class switching, optimizing levels, combination therapy, surgery and trials each have a place, and your history decides which fits. If your first biologic has already stopped working, our notes on Remicade (infliximab) pros and cons cover that drug's strengths and limits. If you are still weighing treatment early on, see whether to start biologics for mild Crohn's.
This article is general information and does not diagnose or recommend treatment. Talk to your IBD team about any decision on your medicines.




